Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2021; 12(5): 355-366
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.355
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study
Chiara Maddalena, Andrea Ponsiglione, Luigi Camera, Lidia Santarpia, Fabrizio Pasanisi, Dario Bruzzese, Camilla Panico, Giovanni Fiore, Simona Camardella, Tolomeo Caramia, Alessia Farinaro, Sabino De Placido, Chiara Carlomagno
Chiara Maddalena, Lidia Santarpia, Fabrizio Pasanisi, Giovanni Fiore, Simona Camardella, Tolomeo Caramia, Alessia Farinaro, Sabino De Placido, Chiara Carlomagno, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples 80131, Italy
Andrea Ponsiglione, Luigi Camera, Camilla Panico, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples 80131, Italy
Dario Bruzzese, Department of Public Health, University of Naples Federico II, Naples 80131, Italy
Author contributions: Maddalena C contributed to the conception and design of the study, acquisition of data, analysis and interpretation of data, and writing the original draft; Ponsiglione A and Panico C contributed to the analysis and interpretation of data; Camera L, Santarpia L and Pasanisi F contributed to the conception and design of the study; Bruzzese D contributed to the biostatistical analysis; Fiore G, Camardella S, Caramia T and Farinaro A contributed to the acquisition of data; De Placido S contributed to the supervision; Carlomagno C contributed to the conception and design of the study, analysis and interpretation of data, supervision, review and editing, and final approval of the version of the article to be published.
Institutional review board statement: The study was approved by the panel of scientists proposing the research and by all the collaborators who participated in the research.
Informed consent statement: Informed written consent was obtained from the patients for publication of this report.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chiara Maddalena, MD, Academic Fellow, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples 80131, Italy. chiara.maddalena@yahoo.it
Received: December 26, 2020
Peer-review started: December 26, 2020
First decision: January 18, 2021
Revised: January 31, 2021
Accepted: March 18, 2021
Article in press: March 18, 2021
Published online: May 24, 2021
Core Tip

Core Tip: According to previous studies, sarcopenia is associated with a poorer prognosis in metastatic colorectal cancer (mCRC) patients. We analyzed the prognostic role of sarcopenia in 56 mCRC patients treated with first-line chemotherapy. Neither sarcopenia nor muscle mass loss was significantly associated with survival. Other prospective studies are needed to clarify the role of sarcopenia in mCRC patients. Moreover, greater efforts should be made to diagnose sarcopenia earlier to correct strength and muscle mass, and thus improve patient tolerability to treatment and survival.